|
|
Article: Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug.
- Article from:
- Biotech Week
- Article date:
- July 8, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cordex Pharma, Inc. (BULLETIN BOARD: CDXP) announced that it has entered into an agreement with Clinical Trials International, LLC, (CTI), regarding a license to develop and market Cordex's drug candidate, ATPotent(TM) (see also Male Infertility).
ATPotent(TM) is a novel ATP-based drug candidate designed for in vitro (outside of the human body) treatment of sperm in conjunction with intrauterine insemination (IUI) and in vitro fertilization (IVF) procedures. ATPotent(TM) is based on Cordex's proprietary technologies related to the use of adenosine 5'-triphosphate (ATP) for improving human and animal sperm motility and fertilization capacity.
According ...